Trial Details
Not yet recruiting
Area of Research: Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Phase 2/3

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Brief Summary:

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in causing and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: The first line of the email MUST contain the NCT # and Site #.

3 locations available.

Log In

Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create Account

Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

  • 8 characters minimum
  • First character cannot be a number
  • Last character cannot be a number